Key Takeaway
thorough clinical evidence review of GLP-1 receptor agonist cardiovascular benefits. LEADER, SUSTAIN-6, SELECT, and REWIND trial data on MACE reduction and heart protection.
Executive Summary
GLP-1 receptor agonists have established themselves as one of the most impactful classes of medications for cardiovascular risk reduction in patients with type 2 diabetes and, more recently, in patients with obesity regardless of diabetes status. The cardiovascular evidence base now includes eight major cardiovascular outcomes trials (CVOTs) enrolling over 60,000 participants, with consistent findings showing 12 to 26% reductions in major adverse cardiovascular events (MACE). The SELECT trial[2] extended these benefits to patients with obesity without diabetes, and the FLOW trial demonstrated kidney protection. This article reviews the important trial data, quantifies the cardiovascular benefit, and examines the mechanisms underlying GLP-1-mediated cardiovascular protection.
Clinical Evidence: The Cardiovascular Outcomes Trial Portfolio
Defining the Primary Endpoint: MACE
Cardiovascular outcomes trials for diabetes medications use a standardized primary endpoint called 3-point MACE (Major Adverse Cardiovascular Events), which includes cardiovascular death, nonfatal myocardial infarction (heart attack), and nonfatal stroke. Some trials also report expanded MACE that includes hospitalization for unstable angina. All events are adjudicated by independent committees blinded to treatment assignment .
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
LEADER Trial (Liraglutide)
The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial randomized 9,340 patients with type 2 diabetes and high cardiovascular risk to liraglutide 1.8 mg daily or placebo, with a median follow-up of 3.8 years .
- Primary endpoint (3-point MACE): 13% reduction (HR 0.87, 95% CI 0.78 to 0.97, p=0.01)
- Cardiovascular death: 22% reduction (HR 0.78, 95% CI 0.66 to 0.93)
- All-cause mortality: 15% reduction (HR 0.85, 95% CI 0.74 to 0.97)
- Nonfatal MI: Non-significant 12% reduction
- Nonfatal stroke: Non-significant 11% reduction
LEADER was the first trial to establish cardiovascular superiority for a GLP-1 agonist and fundamentally changed treatment algorithms for type 2 diabetes. The cardiovascular death reduction was the primary driver of the MACE benefit.
SUSTAIN-6 Trial (Semaglutide)
SUSTAIN-6 randomized 3,297 patients with type 2 diabetes and established cardiovascular disease or cardiovascular risk factors to subcutaneous semaglutide (0.5 mg or 1.0 mg weekly) or placebo for 2.1 years .
- Primary endpoint (3-point MACE): 26% reduction (HR 0.74, 95% CI 0.58 to 0.95, p=0.02)
- Nonfatal stroke: 39% reduction (HR 0.61, 95% CI 0.38 to 0.99)
- Nonfatal MI: Non-significant 26% reduction
- Cardiovascular death: Non-significant 2% reduction
SUSTAIN-6 showed the largest MACE reduction among the GLP-1 CVOTs, driven primarily by stroke prevention. The trial was designed as a safety study with a relatively short duration, which limited its statistical power for individual endpoint analyses.
REWIND Trial (Dulaglutide)
REWIND randomized 9,901 patients with type 2 diabetes to dulaglutide 1.5 mg weekly or placebo, with a median follow-up of 5.4 years. only 31% of participants had established cardiovascular disease, making this the first CVOT to demonstrate benefit in a predominantly primary prevention population .
- Primary endpoint (3-point MACE): 12% reduction (HR 0.88, 95% CI 0.79 to 0.99, p=0.026)
- Nonfatal stroke: 24% reduction (HR 0.76, 95% CI 0.62 to 0.94)
- All-cause mortality: Non-significant 10% reduction
REWIND was significant because it showed that cardiovascular benefit isn't limited to patients with established heart disease, suggesting a role for GLP-1 agonists in cardiovascular primary prevention in high-risk diabetes patients.
HARMONY Outcomes (Albiglutide)
HARMONY Outcomes randomized 9,463 patients with type 2 diabetes and cardiovascular disease to albiglutide 30-50 mg weekly or placebo, with a median follow-up of 1.6 years .
- Primary endpoint (3-point MACE): 22% reduction (HR 0.78, 95% CI 0.68 to 0.90, p<0.001)
- Nonfatal MI: 25% reduction (HR 0.75, 95% CI 0.61 to 0.90)
Despite albiglutide's subsequent withdrawal from the market for commercial reasons, the HARMONY data provided important confirmation that cardiovascular protection is likely a class effect of long-acting GLP-1 agonists.
SELECT Trial (Semaglutide in Obesity Without Diabetes)
The SELECT trial was a landmark study that extended GLP-1 cardiovascular evidence beyond the diabetes population. It randomized 17,604 adults with overweight or obesity (BMI 27 or higher) and established atherosclerotic cardiovascular disease, but without diabetes, to semaglutide 2.4 mg weekly or placebo, with a mean follow-up of 39.8 months .
- Primary endpoint (3-point MACE): 20% reduction (HR 0.80, 95% CI 0.72 to 0.90, p<0.001)
- Cardiovascular death: 15% reduction (HR 0.85, 95% CI 0.71 to 1.01, borderline non-significant)
- Nonfatal MI: 28% reduction (HR 0.72, 95% CI 0.61 to 0.85)
- Nonfatal stroke: 7% reduction (HR 0.93, 95% CI 0.74 to 1.15, non-significant)
- All-cause mortality: 19% reduction (HR 0.81, 95% CI 0.71 to 0.93)
SELECT established that the cardiovascular benefits of GLP-1 agonism aren't dependent on glucose lowering, fundamentally repositioning these agents from "diabetes drugs with cardiovascular benefits" to "cardiovascular drugs that also treat diabetes and obesity."
Trials Showing Safety Without Superiority
Two GLP-1 agonist CVOTs showed cardiovascular safety but did not achieve statistical superiority:
- ELIXA (lixisenatide): HR 1.02 (95% CI 0.89 to 1.17) for MACE over 2.1 years. Lixisenatide is a short-acting agent, and the lack of benefit may reflect insufficient duration of GLP-1 receptor engagement
- EXSCEL (exenatide extended-release): HR 0.91 (95% CI 0.83 to 1.00, p=0.06) for MACE over 3.2 years. This narrow miss suggested a trend toward benefit but did not reach statistical significance
Meta-Analytic Evidence
A thorough meta-analysis of all eight GLP-1 agonist CVOTs (60,080 participants) found :
- 3-point MACE: 14% reduction (HR 0.86, 95% CI 0.80 to 0.93)
- All-cause mortality: 12% reduction (HR 0.88, 95% CI 0.82 to 0.94)
- Heart failure hospitalization: 11% reduction (HR 0.89, 95% CI 0.82 to 0.98)
- Composite kidney outcome: 17% reduction (HR 0.83, 95% CI 0.78 to 0.89)
Subgroup analyses found consistent benefit regardless of baseline HbA1c, BMI, age, sex, or kidney function, supporting broad applicability of the cardiovascular benefit.
FLOW Trial: Kidney and Cardiovascular Intersection
The FLOW trial randomized 3,533 patients with type 2 diabetes and chronic kidney disease to semaglutide 1.0 mg or placebo. The primary composite kidney endpoint was reduced by 24% (HR 0.76, 95% CI 0.66 to 0.88). Cardiovascular death (a component of the composite) was reduced by 29%. The trial was stopped early for efficacy, making it the first dedicated kidney outcomes trial to demonstrate benefit for a GLP-1 agonist .
Mechanism: How GLP-1 Agonists Protect the Cardiovascular System
The cardiovascular benefits of GLP-1 agonists are mediated by multiple mechanisms operating simultaneously. Research has established that these benefits extend well beyond glucose lowering.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Atherosclerosis Reduction
GLP-1 agonists reduce several key drivers of atherosclerotic plaque development:
- Lipid improvements: Reductions in triglycerides (8 to 25%), VLDL cholesterol, and ApoC-III decrease the atherogenic lipoprotein burden
- Blood pressure reduction: Sustained systolic BP reductions of 3 to 7 mmHg reduce shear stress on arterial walls and slow plaque progression
- Anti-inflammatory effects: Reductions in CRP (20 to 40%), IL-6, and TNF-alpha reduce the inflammatory milieu that drives plaque instability and rupture
- Improved endothelial function: Enhanced flow-mediated dilation and increased nitric oxide bioavailability restore protective endothelial function
Direct Cardiac Effects
GLP-1 receptors are expressed in the human heart, including in cardiomyocytes and the sinoatrial node. Research in human subjects has identified several direct cardiac effects:
- Improved myocardial glucose uptake: PET imaging studies have shown increased myocardial glucose use during GLP-1 infusion, which may protect the heart during ischemic stress
- Improved left ventricular function: Echocardiographic studies have demonstrated improvements in diastolic function parameters with GLP-1 agonist therapy, including improved E/A ratio and reduced left atrial volume index
- Reduced cardiac lipotoxicity: By reducing circulating free fatty acids and improving cardiac substrate use, GLP-1 agonists may reduce lipid-mediated cardiac damage
Preclinical studies in animal models of myocardial infarction have shown that GLP-1 receptor activation reduces infarct size, but these findings haven't been tested in dedicated human clinical trials of acute MI .
Weight Loss and Metabolic Improvement
Mediation analyses from the SELECT trial estimated that weight loss accounted for approximately 40% of the MACE reduction, with the remainder attributed to weight-independent mechanisms . This is consistent with the understanding that GLP-1 agonists provide both direct vascular/cardiac protection and indirect benefit through metabolic improvement.
Kidney Protection and Cardiovascular Risk
Chronic kidney disease is one of the strongest cardiovascular risk multipliers. By slowing kidney disease progression (as demonstrated in FLOW), GLP-1 agonists may indirectly reduce cardiovascular events through preserved kidney function, better fluid balance, and reduced uremic toxin exposure .
Safety Profile
Cardiovascular Safety
The cardiovascular safety of GLP-1 agonists is strongly supported by the CVOT program. No agent has shown cardiovascular harm, and several have demonstrated clear benefit. Specific cardiovascular safety considerations include:
- Heart rate: GLP-1 agonists increase resting heart rate by 2 to 4 bpm. This has been observed consistently across the class. Despite theoretical concerns, the CVOTs haven't shown any increase in arrhythmias, heart failure, or cardiovascular death attributable to this heart rate increase. The net cardiovascular effect is strongly protective
- Heart failure: The meta-analysis of CVOTs showed an 11% reduction in heart failure hospitalization. No individual trial has shown increased heart failure risk. This distinguishes GLP-1 agonists from some other diabetes medications (such as thiazolidinediones) that increase heart failure risk
- Arrhythmia: Large-scale trial[3] data don't show increased risk of atrial fibrillation, ventricular arrhythmia, or sudden cardiac death
General Safety Profile
The overall safety profile is consistent across the GLP-1 agonist class. Gastrointestinal side effects (nausea, vomiting, diarrhea) are the most common, occurring in 15 to 25% of patients and typically resolving over weeks. Rare but serious risks include pancreatitis, gallbladder events, and the thyroid C-cell tumor concern based on rodent studies. The boxed warning for thyroid C-cell tumors applies to all GLP-1 agonists. human epidemiological data spanning over 15 years haven't confirmed an increased risk of medullary thyroid carcinoma .
Retinopathy Consideration
SUSTAIN-6 identified a signal for diabetic retinopathy complications with semaglutide. Analysis suggested this was related to rapid HbA1c improvement in patients with pre-existing retinopathy, a phenomenon also observed with insulin intensification, rather than a direct drug effect. The SELECT trial (in patients without diabetes) showed no retinopathy signal. Patients with pre-existing diabetic retinopathy should have ophthalmologic monitoring when initiating GLP-1 therapy .
Practical Implications
The cardiovascular evidence for GLP-1 agonists has fundamentally reshaped treatment guidelines:
Guideline positioning: The ADA Standards of Care (2024) and the ESC/EASD cardiovascular disease guidelines recommend GLP-1 agonists with proven cardiovascular benefit (liraglutide, semaglutide, dulaglutide) as preferred agents for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, independent of HbA1c. cardiovascular protection, not glucose control, is the primary rationale for prescribing in these patients .
Beyond diabetes: The SELECT trial has prompted guideline updates to consider semaglutide 2.4 mg for cardiovascular risk reduction in patients with obesity and established cardiovascular disease, regardless of diabetes status. This significantly expands the eligible population.
Combination with SGLT2 inhibitors: GLP-1 agonists and SGLT2 inhibitors have complementary cardiovascular mechanisms. GLP-1 agonists primarily reduce atherosclerotic events (MI, stroke), while SGLT2 inhibitors have stronger effects on heart failure hospitalization. Many experts recommend using both in high-risk patients, though this combination hasn't been tested in a dedicated outcomes trial .
Agent selection: Among GLP-1 agonists with proven cardiovascular benefit, semaglutide has shown the largest MACE reduction in both diabetes (SUSTAIN-6: 26%) and obesity (SELECT: 20%[2]). Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing and will determine whether the dual GIP/GLP-1 agonist provides additional cardiovascular benefit beyond GLP-1 agonism alone .
Early intervention: The REWIND trial demonstrated benefit in a primary prevention population (69% without established CVD). This suggests that waiting until cardiovascular disease is established before initiating GLP-1 therapy may represent a missed opportunity for prevention.
Frequently Asked Questions
Which GLP-1 agonist has the strongest cardiovascular evidence?
Semaglutide currently has the most thorough cardiovascular evidence, with proven MACE reduction in both type 2 diabetes (SUSTAIN-6: 26% reduction) and obesity without diabetes (SELECT: 20%[2] reduction), plus kidney protection in the FLOW trial. Liraglutide (LEADER) and dulaglutide (REWIND) also have strong cardiovascular outcomes data. Among available agents with proven cardiovascular benefit, semaglutide has shown the largest magnitude of MACE[2] reduction .
Do GLP-1 agonists reduce heart failure risk?
The meta-analysis of GLP-1 CVOTs showed an 11% reduction in heart failure hospitalization (HR 0.89, 95% CI 0.82 to 0.98). But the effect on heart failure is more modest than the effect on atherosclerotic events, and no individual trial showed a statistically significant heart failure reduction. SGLT2 inhibitors have stronger and more consistent evidence for heart failure prevention. For patients with both heart failure and atherosclerotic risk, combining GLP-1 agonists with SGLT2 inhibitors may offer the most thorough cardiovascular protection .
Are the cardiovascular benefits related to blood sugar improvement?
Partially, but not entirely. The SELECT trial demonstrated a 20% MACE reduction in patients without diabetes, indicating that cardiovascular protection occurs independent of glucose lowering. Mediation analyses from multiple trials estimate that glucose lowering accounts for a relatively small proportion of the total cardiovascular benefit, with weight loss, blood pressure reduction, lipid improvements, and direct vascular/anti-inflammatory effects contributing substantially .
How quickly do the cardiovascular benefits appear?
Kaplan-Meier curves from the CVOTs typically show separation between GLP-1 agonist and placebo groups beginning at 12 to 18 months. This lag is consistent with the time required for atherosclerotic plaque stabilization, weight loss, and vascular remodeling. But some benefit may accrue earlier through blood pressure reduction and anti-inflammatory effects. Clinicians should set expectations that cardiovascular protection is a long-term benefit rather than an immediate effect .
Should every patient with type 2 diabetes be on a GLP-1 agonist?
Current guidelines recommend GLP-1 agonists with proven cardiovascular benefit for patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. For patients without these conditions, the decision depends on individual factors including need for weight management, glycemic control, cost, and patient preferences. Cost remains a significant barrier to broader use, though the expansion of indications and potential for generic competition may improve access over time .
Medical References
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. [PubMed | ClinicalTrials.gov | DOI]
Take the Next Step
If you're concerned about your cardiovascular risk and want to explore whether a GLP-1 receptor agonist could benefit your heart health, our physician-supervised telehealth platform connects you with licensed providers who specialize in GLP-1 and peptide therapy. Start your consultation today for a personalized evaluation of your cardiovascular and metabolic health.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →